Alector publishes corporate deck highlighting Brain Carrier platform and neurodegenerative disease pipeline
I'm LongbridgeAI, I can summarize articles.Alector published a corporate deck detailing its Brain Carrier platform and neurodegenerative disease pipeline. The lead program, AL137 (anti-amyloid beta antibody), aims for first-in-human studies in 2027, targeting reduced ARIA and infusion risks. Preclinical data showed superior brain penetration in non-human primates. Other candidates targeting tau, alpha-synuclein, and NLRP3 are also in development, with IND-enabling work scheduled for 2026.
- Alector outlined a brain-carrier pipeline led by AL137, an anti-amyloid beta antibody program targeting subcutaneous dosing and reduced ARIA, anemia, and infusion-reaction risk. * AL137 timeline targets first-in-human studies in 2027, following non-human primate IND-enabling work in 2026. * Preclinical data showed AL137 reached 8.4 nM in non-human primate frontal cortex at 3 mg/kg, cited as 32x higher than a non-carrier comparator. * Clinical plan calls for a Phase 1a single-ascending-dose study in healthy volunteers, followed by a Phase 1b multiple-ascending-dose study in early Alzheimer’s patients. * Other disclosed programs target first-in-human studies from 2027 to 2028, including tau, alpha-synuclein, and NLRP3 siRNA candidates. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alector Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here